Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
According to the National Institute of Health, glutathione is a tripeptide that includes glutamic acid and cysteinylglycine
Reus TL, Brohem CA, Schuck DC, et al
For example, the variant 677T is most commonly associated with cerebral vascular accident (stroke), elevated homocysteine, cardiovascular disease risk, peripheral neuropathy, deep vein thrombosis, early-onset heart disease, stillbirth, neuro-tube defect, cleft lip, and preeclampsia
GHK-Cu injections deliver the copper peptide complex directly into targeted tissues typically via subcutaneous injection